Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Por:
E. JANTUS-LEWINTRE, B. SUREDA, J. LARRIBA, D. RODRIGUEZ-ABREU, O. JUAN, A. BLASCO, M. DOMINE, M. PULLA, J. GARDE, R. ALVAREZ, I. MAESTU, R. DE CARRION, A. ARTAL, C. ROLFO, J. DE CASTRO, M. GUILLOT, J. ORAMAS, R. DE LAS PENAS, L. FERRERA, N. MARTINEZ, O. SERRA, R. ROSELL, C. CAMPS and Grp Espanol Canc Pulmon GECP
Publicada:
26 jul 2021
Resumen:
Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy.
Filiaciones:
:
Univ Politecn Valencia, Fdn Invest Hosp Gen Univ Valencia, Unidad Mixta TRIAL, Ctr Invest Principe Felipe,CIBERONC,Dept Biotecno, Valencia, Spain
B. SUREDA:
Hosp Gen Univ Alicante, Serv Oncol Med, Alicante, Spain
J. LARRIBA:
Univ San Carlos, Hosp Clin, Serv Oncol Med, Madrid, Spain
D. RODRIGUEZ-ABREU:
Univ Palmas De Gran Canaria, Complejo Hosp Univ Insular Materno Infantil Gran, Las Palmas Gran Canaria, Spain
O. JUAN:
Hosp Politecn & Univ La Fe, Serv Oncol Med, Valencia, Spain
A. BLASCO:
Consorcio Hosp Gen Univ Valencia, CIBERONC, Valencia, Spain
M. DOMINE:
Hosp Univ Fdn Jimenez Diaz, Serv Oncol Med, Madrid, Spain
M. PULLA:
Hosp Univ Puerta Hierro, Serv Oncol Med, Majadahonda, Spain
J. GARDE:
Hosp Arnau Vilanova, Dept Oncol Med, Valencia, Spain
R. ALVAREZ:
Hosp Gen Univ Gregorio Maranon, Dept Oncol Med, Madrid, Spain
I. MAESTU:
Hosp Univ Doctor Peset, Dept Oncol Med, Valencia, Spain
R. DE CARRION:
Hosp Univ Quironsalud, Serv Oncol Med, Madrid, Spain
A. ARTAL:
Hosp Univ Miguel Servet, Serv Oncol Med, Zaragoza, Spain
C. ROLFO:
Univ Maryland, Sch Med, Greenbaum Comprehens Canc Ctr, Expt Therapeut Program, Baltimore, MD USA
J. DE CASTRO:
Hosp Univ La Paz, Serv Oncol Med, Madrid, Spain
M. GUILLOT:
Hosp Son Espases, Serv Oncol Med, Palma de Mallorca, Spain
J. ORAMAS:
Hosp Univ Canarias, Dept Oncol Med, Santa Cruz De Tenerife, Spain
R. DE LAS PENAS:
Hosp Prov Castello, Dept Oncol Med, Castellon de La Plana, Spain
L. FERRERA:
Hosp Univ Nuestra Senora Candelaria, Serv Oncol Med, Santa Cruz De Tenerife, Spain
N. MARTINEZ:
Hosp Gen Univ Elche, Dept Oncol, Elche, Spain
O. SERRA:
Hosp Gen lHosp, Dept Oncol Med, Lhospitalet De Llobregat, Spain
R. ROSELL:
Inst Recerca Germans Trias & Pujol, Programa Biol Canc & Med Precis, Badalona, Spain
Inst Oncol Dr Rosell, Barcelona, Spain
:
Univ Politecn Valencia, Fdn Invest Hosp Gen Univ Valencia, Ctr Invest Principe Felipe,CIBERONC, Unidad Mixta TRIAL,Dept Med, Valencia, Spain
Green Published, gold
|